Research and Markets: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics Pipeline Report 2015 - 22 Companies & 30 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3cj3wx/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • AstraZeneca PLC
  • Athersys, Inc.
  • Bayer AG
  • Betagenon AB
  • Cardiolynx AG
  • CardioVascular BioTherapeutics, Inc.
  • Celgene Corporation
  • Diffusion Pharmaceuticals LLC
  • DNAVEC Corporation
  • KunWha Pharmaceutical Co., Ltd.
  • MedImmune, LLC
  • miRagen Therapeutics, Inc.
  • Multi Gene Vascular Systems Ltd
  • Nuo Therapeutics, Inc.
  • Proteon Therapeutics, Inc.
  • Recardio GmbH
  • RegenoCELL Therapeutics, Inc.
  • Resverlogix Corp.
  • Sagene Pharmaceuticals, Inc.
  • Stemedica Cell Technologies, Inc.
  • Theravasc, Inc.
  • ViroMed Co., Ltd.

Drug Profiles

  • (cilostazol + organic nitrate) ER
  • AEM-28
  • ALD-301
  • Annexin A-5
  • CVBT-141C
  • DVC1-0101
  • ELS-140
  • Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease
  • Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders
  • MEDI-6012
  • Mesenchymal Stem Cells
  • MGN-6114
  • MultiGeneAngio
  • MultiGeneGraft
  • MultiStem
  • O-304
  • PDA-002
  • REC-03
  • rivaroxaban
  • RVX-208
  • sarpogrelate SR
  • selegiline + Antiplatelet Drugs
  • sodium nitrite SR
  • Stem Cell Therapy for Cardiovascular Diseases
  • SYN-20112312RU
  • ticagrelor
  • transcrocetinate sodium
  • TXA-127
  • VM-202
  • vonapanitase

For more information visit http://www.researchandmarkets.com/research/3cj3wx/peripheral

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular